### Special Features

**New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways**

Arvind Dasari and Wells A. Messersmith

**Killing the Killer: Natural Killer Cells to Treat Ewing’s Sarcoma**

Yong-Oon Ahn, Brenda Weigel, and Michael R. Verneris

**Fluorescence Resonance Energy Transfer Biosensors for Cancer Detection and Evaluation of Drug Efficacy**

Shaoying Lu and Yingxiao Wang

**Deregulated Intracellular Signaling by Mutated c-CBL in Myeloid Neoplasms**

Seishi Ogawa, Lee-Yung Shih, Takahiro Suzuki, Makoto Otsu, Hiromitsu Nakauchi, H. Phillip Koeffler, and Masashi Sanada

### Predictive Biomarkers and Personalized Medicine

**Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk**

Zhe-Yi Hu, Qi Yu, Qi Pei, and Cheng Guo

### Human Cancer Biology

**Sperm DNA Integrity in Men Treated for Childhood Cancer**

Patrik Romerius, Olof Ståhl, Christian Moell, Thomas Relander, Eva Cavallin-Ståhl, Helen Gustafsson, Kerstin Löfvenard Thapper, Katarina Jepson, Marcello Spanò, Thomas Wiebe, Yvonne Lundberg Giwercman, and Aleksander Giwercman

**GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas**

Patrick Roth, Markus Junker, Isabel Tritschler, Michel Mittelbron, Yvonne Dombrowski, Samuel N. Breit, Ghazaleh Tabatabai, Wolfgang Wick, Michael Weller, and Jörg Wischhusen

**Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma**

Toshima Z. Parris, Anna Daniellson, Szilárd Nemes, Anikó Kovács, Ulla Delle, Ghita Fallenius, Elin Möllerström, Per Karlsson, and Khalil Helou

**CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis**

Gong Yang, Daniel G. Rosen, Guangzhi Liu, Fan Yang, Xiaojing Guo, Xue Xiao, Fengxia Xue, Imelda Mercado-Uribe, Jiaoti Huang, Sue-Hwa Lin, Gordon B. Mills, and Jinsong Liu

**Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy**

Anil Bagri, Leanne Berry, Bert Gunter, Mallika Singh, Jan Kasman, Lisa A. Damico, Hong Xiang, Maike Schmidt, Germaine Fuh, Beth Hollister, Oliver Rosen, and Greg D. Plowman
A Novel FRET-Based Biosensor for the Measurement of BCR-ABL Activity and Its Response to Drugs in Living Cells
Tatsuki Mizutani, Takeshi Kondo, Stephanie Darmanin, Masumi Tsuda, Shinya Tanaka, Minoru Tobiume, Masahiro Asaka, and Yusuke Ohba
See commentary p. 3822

Genetically Abnormal Circulating Cells in Lung Cancer Patients: An Antigen-Independent Fluorescence in situ Hybridization–Based Case-Control Study

BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy
Charles Dumontet, Maryla Krajewska, Isabelle Treilleux, John R. Mackey, Miguel Martin, Mathieu Rupin, Laurence Lafanèchère, and John C. Reed

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients
Pier Luigi Zinzani, Giuseppe Rossi, Silvia Franceschetti, Barbara Botto, Alice Di Rocco, Maria Giuseppina Cabras, Maria Concetta Petti, Vittorio Stefoni, Alessandro Broccoli, Stefano Fanti, Cinzia Pellegrini, Gian Carlo Montini, Letizia Gandolfi, Enrico Derenzini, Lisa Argnani, Mariapaola Fina, Alessandra Tucci, Chiara Bottelli, Stefano Pileri, and Michele Baccarani
CXC chemokine receptor 2 (CXCR2) expression in an ovarian cancer cell line detected by the immunofluorescent staining. Overexpression of CXCR2 in ovarian cancer cells leads to dysregulation of cell cycle, decreased apoptosis, and increased angiogenesis. The high level expression of CXCR2 also predicts poor prognosis in patients with high-grade ovarian serous carcinoma. For further details, please see the article by Yang and colleagues on page 3875 of this issue.